- Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS.
- The company's treatment appears to be different from other treatments. Enzolytics Inc. claims to be offering a product with zero toxicity issues, minor side effects, and cost savings.
- According to their website, they have tested 31 patients. Besides, they are about to acquire a new laboratory, which will most likely be operational in June 2021.
- Enzolytics Inc. targets a market that could be close to $37 billion in 2027. That's a large market size. However, numerous companies are already selling HIV drugs. The competition in the market is significant.
- Enzolytics Inc. may need to test hundreds of patients. The process will also take a lot of time and financial resources. Shareholders need to understand well that they may have to wait many years until Enzolytics Inc. can report sales.
For further details see:
Risky Enzolytics Inc. Delivered Triple-Digit Stock Returns